Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Client Area Book a 7-day Readout
NMD Pharma A/S logo — A clinical-stage biotech company focused on developing life-...

NMD Pharma A/S

A clinical-stage biotech company focused on developing life-changing therapies for neuromuscular diseases.

Founded 2015 Denmark Denmark 61 employees Series B Total: $151.03M Health and Wellness, Pharmaceutical

General Information

Company Name NMD Pharma A/S
Founded Year 2015
Location Denmark Denmark
Founders / Decision Makers
Team member Team member Team member
Employees 61
Industries Health and Wellness, Pharmaceutical
Funding Stage Series B
Social

BounceWatch is an independent company data service, not affiliated with NMD Pharma A/S. To contact NMD Pharma A/S, visit nmdpharma.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does NMD Pharma A/S compare?

A PDF of NMD Pharma A/S and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting NMD Pharma A/S soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About NMD Pharma A/S

NMD Pharma A/S is a clinical-stage biotech company focused on developing life-changing therapies for neuromuscular diseases. Their mission is to develop novel treatments to improve muscle function and quality of life for patients with neuromuscular disease. They aim to create a future where patients with neuromuscular diseases live better and more independent lives. The company has a unique translational muscle electrophysiology platform leveraging in-depth know-how of muscle physiology and muscular disorders for discovering and developing first-in-class therapeutics in neuromuscular diseases with a significant unmet medical need. NMD Pharma is the leading company utilizing ClC-1 Cl- ion channel inhibitors for neuromuscular diseases and currently has one clinical-stage product candidate for the treatment of myasthenia gravis. Established in 2015 and headquartered in Aarhus, Denmark, the company has more than 25 employees with expertise in all areas of drug development. They collaborate with internationally renowned companies and key opinion leaders in the field of neuromuscular diseases. NMD Pharma recently received a €75.00M Series B investment on 15 November 2023 from investors including Novo Holdings, Jeito Capital, Roche Venture Fund, Inkef, and Lundbeckfonden Emerge. For more information, please visit the company website.

Business keywords: clinical-stage biotech, neuromuscular diseases, therapeutics, ClC-1 Cl- ion channel inhibitors, muscle electrophysiology, drug development, myasthenia gravis, muscle physiology, translational research, neurological disorders, biopharmaceuticals

Services & Products

Discovering and developing novel therapeutics for neuromuscular diseases

Target Customers

Patients suffering from neuromuscular diseases healthcare providers biopharmaceutical companies investors

Funding Rounds & Investors (5)

View All
Funding Stage Amount Investors Lead Investors Date
Series B €75.00M 5
Novo Holdings Jeito Capital Roche Venture Fund
Novo Holdings, Jeito Capital +3
15 Nov 2023
Venture Round €35.00M 5
Novo Holdings Jeito Capital Roche Venture Fund
Novo Holdings, Jeito Capital +3
15 Feb 2022
Series A €38.00M 4
Novo Holdings Roche Venture Fund Inkef
Novo Holdings, Roche Venture Fund +2
23 Mar 2018
Venture Round €2.70M 3
Novo Holdings CAPNOVA
Novo Holdings, CAPNOVA +1
01 Jul 2016
Grant €330.00K 1
Novo Holdings
Novo Holdings
01 Jan 2016

NMD Pharma A/S Alternatives & Competitors

View All Alternatives
NMD Pharma A/S vs
Cajal Therapeutics
Cajal Therapeutics United States

Cajal Therapeutics is a Seattle biotechnology company dedicated to developing innovative medicines f...

Series A
38 employees
Biotechnology, Health and Wellness
Compare NMD Pharma A/S vs Cajal Therapeutics
NMD Pharma A/S vs
iN Therapeutics
iN Therapeutics Korea South

의학 및 약학 연구개발업

Series B
8 employees
Biotechnology, Health and Wellness
Compare NMD Pharma A/S vs iN Therapeutics
NMD Pharma A/S vs
Microbion Corporation
Microbion Corporation United States

Developing a disruptive new class of therapeutic drugs for the treatment of rare, chronic, and serio...

Venture round
16 employees
Biotechnology, Health Care
View all alternatives

FAQ About NMD Pharma A/S

A clinical-stage biotech company focused on developing life-changing therapies for neuromuscular diseases.
NMD Pharma A/S was founded in 2015.
NMD Pharma A/S is headquartered in Denmark.
NMD Pharma A/S operates in Health and Wellness and Pharmaceutical. Its work centres on clinical-stage biotech, neuromuscular diseases, therapeutics and ClC-1 Cl- ion channel inhibitors. Its customers include Patients suffering from neuromuscular diseases, healthcare providers and biopharmaceutical companies.
NMD Pharma A/S has approximately 61 employees.
NMD Pharma A/S has completed 5 funding rounds, raising a total of $151.03M. The latest funding stage is Series B.
NMD Pharma A/S offers: Discovering and developing novel therapeutics for neuromuscular diseases.
Top alternatives and competitors to NMD Pharma A/S include Cajal Therapeutics, iN Therapeutics, Microbion Corporation, Cerevance, Emalex Biosciences. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
NMD Pharma A/S and Cajal Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for NMD Pharma A/S, https://bouncewatch.com/company/nmd-pharma-as, updated 24 February 2025. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout